Clinical response of ovarian cysts in dairy cows after PRID treatment.
We investigated the therapeutic effects of a progesterone releasing intravaginal device (PRID) on cystic ovarian disease (COD) and reproduction performance of cows. The possible influence of PRID on metabolic and/or health status was also examined. A total of 40 Holstein-Friesian cattle, with ovarian cystic structures, > or =2.5 cm in diameter, persisting for more than 7-14 days, without a corpus luteum (CL) were used for the study. PRID or placebos were inserted into the vagina for 12 days. Five animals lost the intravaginal device before removal and one was culled. Based on plasma progesterone concentration on the day of treatment, 20 (17 PRID and 3 placebos) of the remaining 34 cows had follicular cysts (progesterone < or =1 ng/ml) and 14 (10 PRID and 4 placebos) had luteal cysts (progesterone >1 ng/m l). Fourteen (82%) of the PRID-treated follicular cystic cows responded with formation of a CL within 14 days after treatment, and an overall conception rate of 53.8%. Likewise, 70% of the treated luteal cystic cows responded with CL formation and 71.4% conception rate. No significant differences were observed in hematocrit (Ht), white blood cell count and serum levels of glucose, blood urea nitrogen, aspartate aminotransferase, and alanine aminotransferase, between the day of PRID insertion and removal, in animals with follicular and luteal cysts. PRID treatment resulted in ovulation 2-4 days later and formation of a CL in cows that recovered.
Zulu
Victor Chisha
VC
Department of Obstetrics and Gynecology, Graduate School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan.
Nakao
Toshihiko
T
Yamada
Kyoji
K
Moriyoshi
Masaharu
M
Nakada
Ken
K
Sawamukai
Yutaka
Y
D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000097:blood / Q000188:drug therapy*; D005260:Female; D010048:Ovarian Cysts / Q000097:blood / Q000188:drug therapy* / Q000662:veterinary*; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D012098:Reproduction / Q000187:drug effects
D011374:Progesterone